HC Wainwright & Co. Maintains Buy on Sana Biotechnology, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Sana Biotechnology (NASDAQ:SANA) but lowers the price target from $12 to $11.

August 09, 2024 | 8:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Sana Biotechnology but lowers the price target from $12 to $11.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates a slightly more conservative outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100